Jefferies Group Comments on Evolent Health Inc’s FY2017 Earnings (EVH)

Evolent Health Inc (NYSE:EVH) – Equities researchers at Jefferies Group reduced their FY2017 earnings per share estimates for shares of Evolent Health in a note issued to investors on Tuesday. Jefferies Group analyst S. Dodge now anticipates that the technology company will earn ($0.57) per share for the year, down from their prior forecast of ($0.56). Jefferies Group currently has a “Buy” rating and a $22.00 price target on the stock. Jefferies Group also issued estimates for Evolent Health’s Q1 2018 earnings at ($0.02) EPS, Q2 2018 earnings at ($0.02) EPS, Q3 2018 earnings at ($0.01) EPS, Q4 2018 earnings at ($0.01) EPS, FY2018 earnings at ($0.06) EPS and FY2019 earnings at $0.19 EPS.

EVH has been the topic of several other reports. Citigroup began coverage on shares of Evolent Health in a report on Thursday, January 4th. They set a “buy” rating on the stock. Goldman Sachs Group lowered shares of Evolent Health from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $30.00 price target on shares of Evolent Health in a report on Thursday, November 2nd. Robert W. Baird reaffirmed a “buy” rating and set a $25.00 price target on shares of Evolent Health in a report on Wednesday, November 1st. Finally, Leerink Swann set a $25.00 price target on shares of Evolent Health and gave the company a “buy” rating in a report on Saturday, November 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company’s stock. Evolent Health currently has an average rating of “Buy” and an average price target of $27.40.

Evolent Health (NYSE:EVH) opened at $13.95 on Thursday. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. Evolent Health has a 1-year low of $10.30 and a 1-year high of $27.50.

A number of institutional investors and hedge funds have recently bought and sold shares of EVH. Jane Street Group LLC bought a new stake in Evolent Health during the 4th quarter worth approximately $144,000. SG Americas Securities LLC bought a new stake in Evolent Health during the 3rd quarter worth approximately $156,000. Virtu Financial LLC bought a new stake in Evolent Health during the 4th quarter worth approximately $172,000. Fox Run Management L.L.C. bought a new stake in Evolent Health during the 4th quarter worth approximately $175,000. Finally, IPG Investment Advisors LLC bought a new stake in Evolent Health during the 3rd quarter worth approximately $195,000. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/15/jefferies-group-comments-on-evolent-health-incs-fy2017-earnings-evh.html.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply